Positron Emission Tomography (Pet)

Positron Emission Tomography (PET) is a research method that is used to evaluate the activity of brain tissue. It is based on determining the degree of emission of radioactive particles from radioactive 2-dexiglucose molecules.

2-Dexiglucose is a substance that enters the brain in the same way as glucose. However, the process of its metabolism by functioning neurons proceeds much more slowly. In damaged brain tissues, the metabolic activity of this substance decreases, and the emission of radioactive substances from them is completely absent or significantly reduced if it is possible to determine the output radiation using tomographic scanning equipment.

For the test, the patient is given 2-deoxyglucose, which is usually labeled with radioactive oxygen. The brain is then scanned using tomography equipment, which can detect the output radiation and create a high-resolution image of the brain.

Positron emission tomography is used to diagnose and treat patients with cerebral palsy, as well as some similar diseases associated with brain damage. It can also be used to study various aspects of brain metabolism using other compounds or drugs.

Compared to computed tomography (CT), which is also used to image the brain, PET has several advantages. For example, PET allows us to assess the functional activity of the brain, and not just its anatomical structure. PET can also be used to study certain biological processes in the body, such as metabolism.

Overall, Positron Emission Tomography is a powerful tool for studying the brain and can be useful in diagnosing and treating a number of diseases.

Positron emission tomography (also known as PET) is a medical imaging technique widely used to evaluate the function and structure of the human brain. This type of research is designed to analyze the activity of brain tissue using the radioisotope glucose, which is then converted into nucleotides through metabolism in the body.

One of the key benefits of PET is its ability to accurately detect brain damage and dysfunction, which can be useful in many areas of medicine, including neurology, psychiatry, oncology and cardiology.

During a PET scan, the patient receives an intravenous injection of radioactive glucose (fludeoxyglucose or FDG), which is then distributed throughout the body. Typically, brain imaging scans are performed 35 to 45 minutes after FDG injection to maximize visibility of metabolically active brain tissue and identify tissue-specific diseases. PET provides unique opportunities to study a wide range of functionally important biochemical and cellular processes occurring in the brain. Sometimes PET is used as a specific marker in diagnosing Alzheimer's disease, then the study results in a decrease in the content of neurons, glial cells and myelin in the brain.

One of the most common applications of PET is to evaluate the effectiveness of modern pharmacotherapy for neurodegenerative diseases. Numerous clinical studies have shown that PET provides a more detailed picture of the performance of neurons and can significantly improve the understanding of the mechanisms of their functioning.

The study was also conducted to identify and characterize the process of carbon oxidation in children with congenital hypomyoglycemia. It turned out that FDG PET studies reveal depletion of carbohydrate stores in the brain and spinal cord during prolonged epileptic seizures. The results may indicate an energy deficit required to maintain nervous system function during an attack and support the current concept that cytokinetic maturation of damaged neurons stops energetic processes.

Positional emission tomography (Positronic Emission Tomographie, PET) is a medical imaging technique that is used to visualize the activity of brain tissue in patients with various neurological diseases. It is based on the use of radioactive glucose, which is metabolized by the brain